IPSC

Over the past six months, Century Therapeutics' stock (IPSC) has experienced significant fluctuations, with a 1-month change of -27.6% and a 3-month change of -47.33% as of October 9, 2026, though its year-to-date performance shows a gain of +28.67% and a past year increase of +129.14% to +146.2%. Key events include the presentation of nonclinical data for CNTY-813 at EASD 2026 on October 2, 2026, the appointment of Joseph Truitt to its Board of Directors on September 9, 2026, and the reporting of Second Quarter 2026 Financial Results and Business Updates on August 12, 2026, which highlighted progress with CNTY-813 and CNTY-308, including promising preclinical data for CNTY-813. In January 2026, the company completed an oversubscribed $135 million private placement, extending its cash runway into the first quarter of 2029. Recently, Century Therapeutics received a Nasdaq deficiency letter regarding the minimum bid price requirement, leading to its transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market. A major risk identified is substantial shareholder dilution, with a 111% increase in shares outstanding in the past year.